536565 NOVELIX

Novelix Pharmaceuticals Share Price

 

 

Start SIP in NOVELIX

Start SIP
Novelix Pharmaceuticals live price: ₹55. It opened at ₹51 vs previous close ₹54; intraday high/low: ₹59/₹51. The 50 & 200 DMA stand at ₹57.41/₹48.25.

Novelix Pharmaceuticals Performance

  • Today's Low
  • ₹51
  • Today's High
  • ₹59
  • 52 Week Low
  • ₹27
  • 52 Week High
  • ₹70
  • Open Price₹51
  • Previous Close₹54
  • Volume1,048
  • 50 DMA₹57.41
  • 100 DMA₹55.44
  • 200 DMA₹48.25

Investment Returns

  • Over 1 Month -12.64%
  • Over 3 Month -11.23%
  • Over 6 Month + 44.32%
  • Over 1 Year + 106.69%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 53
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 97
  • P/B Ratio
  • 3.3
  • Average True Range
  • 4.62
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.51
  • RSI
  • 40.94
  • MFI
  • 12.02

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹55.00
+ 1.23 (2.29%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹56.01
  • 50 Day
  • ₹57.41
  • 100 Day
  • ₹55.44
  • 200 Day
  • ₹48.25

Resistance and Support

54.28 Pivot Speed
  • R3 66.07
  • R2 62.33
  • R1 58.02
  • S1 49.97
  • S2 46.23
  • S3 41.92

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novelix Pharmaceuticals Ltd has an operating revenue of Rs. 127.97 Cr. on a trailing 12-month basis. An annual revenue growth of 578% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 0% is poor and needs improvement. The company has a debt to equity of 53%, which is bit higher. The stock from a technical standpoint is trading below to its 50DMA and around 11% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 23% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 93 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
2025-06-24 Others Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company.
2025-05-27 Audited Results

Novelix Pharmaceuticals F&O

Novelix Pharmaceuticals Shareholding Pattern

46.51%
48.88%
4.61%

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹55 As on 20 March, 2026 | 20:12

The Market Cap of Novelix Pharmaceuticals is ₹96.9 Cr As on 20 March, 2026 | 20:12

The P/E ratio of Novelix Pharmaceuticals is 53 As on 20 March, 2026 | 20:12

The PB ratio of Novelix Pharmaceuticals is 3.3 As on 20 March, 2026 | 20:12

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23